Jump to navigation
About
Mission and Values
Leadership Team
Board of Directors
Medical Advisors
Focus
Hyperoxaluria
Systemic Oxalosis
Hyperuricemia
Publications
Products
Reloxaliase
ALLN-346
Pipeline
FAQs
Investors
Overview
News Releases
Events and Presentations
Stock Information
Analyst Coverage
Corporate Governance
SEC Filings
Shareholder Services
Careers
Contact
Home
Dedicated to Treating Patients
With Rare and Severe
Metabolic Diseases
Utilizing the GI Tract
to Reduce the Burden
of Metabolic Disease
Understanding
Metabolic Diseases
that Affect the Kidney
News
October 5, 2020
Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors
Read more
about Allena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of Directors
September 30, 2020
Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
Read more
about Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
September 8, 2020
Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease
Read more
about Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease
